MedTrace Logo

Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora

NCT04088474 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-09-13

No results posted yet for this study

Summary

This clinical trial was conducted as part of the "Methods for Evaluating the Improvement of Gastrointestinal Function in Health Food" announced by the Department of Health, DOH (currently known as Ministry of Health and Welfare, MOHW) on the test article, "Vigiis 101-LAB powder (Capsules)", manufactured by SunWay Biotech Co., Ltd.

Conditions

  • Gastrointestinal Microbiome

Interventions

DIETARY_SUPPLEMENT

Vigiis 101-LAB

examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)

DIETARY_SUPPLEMENT

Placebo

Maltodextrin was used as a placebo

Sponsors & Collaborators

  • SunWay Biotech Co., LTD.

    lead INDUSTRY

Principal Investigators

  • Jyh Ming Liou, MD,PHD · National Taiwan University Hospital

  • Tsong Ming Lu, MD · Cheng Hsin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-05
Primary Completion
2016-07-06
Completion
2016-12-18

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04088474 on ClinicalTrials.gov